What Is the Prognosis for Diastolic Heart Failure?

Diastolic heart failure carries a five-year survival rate of roughly 43% after a first episode, a figure that puts it in the same ballpark as systolic heart failure over the long term.¹ That number surprises many people, because diastolic heart failure was long considered the “milder” form of the disease. The reality is more complicated, and recent evidence has reshaped how cardiologists think about outcomes. Prognosis depends heavily on which comorbidities are in the mix, how frail the patient is, and whether newer drug therapies are started early.

How Mortality Compares With Systolic Heart Failure

Diastolic heart failure, now more commonly called heart failure with preserved ejection fraction (HFpEF), means the heart’s pumping chamber still squeezes adequately but has become stiff and does not fill properly. Systolic heart failure (HFrEF) is the opposite situation: the chamber fills but does not squeeze well. For years, textbooks taught that the preserved-pumping version carried a better outlook. Newer data have narrowed that gap considerably. Two large retrospective studies found that the one-year all-cause mortality after a hospital admission for diastolic heart failure was 22% and 29%, respectively.² Short-term mortality does appear modestly lower than systolic heart failure: in one registry analysis, the adjusted hazard for death in HFpEF was about 25% lower than in HFrEF over a follow-up of roughly three years.³ But when studies extend beyond five years, mortality between the two types converges.⁴

One reason the long-term numbers look so similar is that the Cardiovascular Health Study found diastolic heart failure actually has a greater attributable mortality rate in the population. Even though individual death rates may be marginally lower, there are simply more people living with HFpEF, so the total burden of deaths is at least as high.² The prevalence of HFpEF has been climbing steadily. In one well-studied U.S. county, HFpEF went from 38% of all heart failure hospitalizations in 1997 to 54% by 2001, driven by a rise in absolute case numbers while systolic heart failure admissions stayed flat.⁵

What People With Diastolic Heart Failure Actually Die From

The mix of causes of death looks different from systolic heart failure, and that matters for treatment decisions. Among all deaths in HFpEF, roughly half to 70% are classified as cardiovascular. Sudden death accounts for about 35% of cardiovascular deaths, and worsening heart failure itself accounts for another 20% or so.⁶ But “sudden death” in this population is a murky category. In clinical trials, roughly a quarter to a third of deaths are labeled sudden, yet it remains unclear how many of those are actually due to fatal heart rhythms versus other acute events like pulmonary embolism or stroke.⁷

The distinguishing feature of HFpEF is that noncardiac causes of death make up a much larger slice of the pie: 30% to 40%, compared with roughly 15% in systolic heart failure.⁶ Infections, kidney failure, cancer, and sepsis are common culprits. This is partly because HFpEF patients tend to be older and carry more noncardiac conditions. It also means that treating only the heart may not be enough to meaningfully change survival; the whole cluster of diseases has to be managed. In one study of over 2,300 patients with diastolic heart failure who died, only 7% died suddenly, while the remaining 93% died of other causes, including progressive heart failure and noncardiac illness.⁸ Noncardiac mortality rates are similar across all ejection fraction categories, reinforcing the idea that the extra noncardiac burden in HFpEF reflects the patient profile rather than the heart failure itself.³

Hospital Readmissions and Their Impact

Getting out of the hospital does not mean staying out. Among nearly 200,000 patients with diastolic heart failure in one national database, about 21% were readmitted within 30 days.⁹ Another smaller study pegged 30-day readmission at 27%.¹⁰ Either way, roughly one in four or five patients bounces back to the hospital within a month. The most common reason for readmission is another episode of acute heart failure, accounting for about 28% of return visits. Infections make up another 10%, and acute kidney injury about 5%.⁹

What predicts readmission? Chronic lung disease, kidney failure, anemia, diabetes, and a high overall burden of other illnesses all raise the odds. A longer hospital stay (more than two days) and being discharged to a nursing or rehab facility rather than home are also red flags.⁹ One frustrating aspect of HFpEF is that standard readmission-prediction tools do a poor job with this population. Commonly used scoring systems showed only slightly better than coin-flip accuracy in predicting which HFpEF patients would be readmitted, which suggests the disease’s heterogeneity overwhelms simple checklist approaches.¹⁰ Dynamic models that incorporate lab values and vital sign trajectories throughout the hospital stay perform better, identifying patients whose risk drops during admission versus those who remain consistently high-risk.¹¹

Comorbidities That Shift the Prognosis

If there is one theme that runs through HFpEF research, it is that coexisting conditions matter enormously. In many patients, the comorbidities may be more dangerous than the heart failure itself.

Kidney Disease

Chronic kidney disease is especially harmful in diastolic heart failure, more so than in systolic heart failure. In a propensity-matched study, kidney disease was associated with 371 extra deaths per 10,000 person-years in diastolic heart failure patients, compared with 214 extra deaths in systolic heart failure patients. The hazard of death climbed in a graded fashion as ejection fraction increased: patients with the highest ejection fractions and kidney disease had more than double the death rate of those without it.¹² Separately, heart failure patients with chronic kidney disease had markedly worse event-free survival (51%) compared with those without kidney problems (87%).¹³

Diabetes

Diabetes makes HFpEF worse in ways that go beyond just adding another diagnosis. In a real-world cohort, diabetes independently raised the risk of death or heart failure hospitalization by about 72% after adjusting for age, body mass, symptom severity, and kidney function.¹⁴ Diabetic HFpEF patients also tended to be younger and heavier, and had higher rates of sleep apnea, suggesting a metabolically driven pattern of disease.

Obesity

Obesity is one of the most common clinical phenotypes of HFpEF and actively promotes disease progression through inflammation, abnormal fat metabolism, and direct mechanical effects on the heart.¹⁵ Diagnosing HFpEF in obese patients is harder, too, because traditional blood markers like NT-proBNP become less reliable in the setting of excess weight.¹⁶ That means obese patients may go undiagnosed longer and present at a more advanced stage.

How Sex, Age, and Frailty Affect Outcomes

HFpEF is more common in women, but the prognostic picture by sex is not straightforward. Men with HFpEF had higher rates of cardiac death (about 17% versus 6%) and were more likely to die from right heart failure or sudden cardiac arrest. Women, by contrast, had higher rates of noncardiac death, particularly from infections. Male sex was independently associated with roughly two and a half times the risk of cardiac death. However, overall all-cause mortality did not differ significantly between men and women once other clinical factors were accounted for.¹⁷

Frailty may be the single strongest modifier of prognosis in HFpEF. In an analysis from the PARAGON-HF trial, the risk of cardiovascular death or heart failure hospitalization more than tripled among the most frail patients compared with the least frail, in a graded fashion.¹⁸ Frailty and diastolic dysfunction severity are each independently associated with future cardiovascular events in older adults, meaning they compound each other.¹⁹ A 75-year-old who can walk briskly, rise from a chair without using their arms, and maintain their weight has a very different outlook from a same-age peer who is losing muscle and struggling with daily tasks, even if both carry the same heart failure diagnosis.

Blood Markers and Risk Scores

One of the most useful single prognostic markers is NT-proBNP, a blood protein released when heart walls are under stress. In a head-to-head analysis, NT-proBNP was the most powerful predictor of death and hospitalization in both HFpEF and HFrEF. The prognostic punch was equivalent: a given NT-proBNP level predicted the same risk regardless of whether the patient had the preserved or reduced form of heart failure, even though baseline levels tend to be lower in HFpEF.²⁰ A rising NT-proBNP over time is a particularly ominous sign.

Several composite risk scores have been validated for HFpEF. The MAGGIC score, which integrates common clinical variables like age, blood pressure, kidney function, and symptom class, is significantly associated with both mortality and heart failure hospitalizations. Adding NT-proBNP on top of the MAGGIC score further improves its predictive power.²¹ The H2FPEF score, designed specifically for diagnosing HFpEF, has also shown some ability to predict outcomes.²² Exercise echocardiography, which adds diastolic measurements during exertion, appears to boost predictive accuracy beyond any resting score alone.²³ None of these tools are perfect, but they help cardiologists sort patients into risk tiers and allocate monitoring resources accordingly.

Treatments That Are Changing the Outlook

For decades, HFpEF was something of a therapeutic desert. Drug after drug that worked in systolic heart failure failed to improve outcomes when tested in the preserved-ejection-fraction population. That changed with SGLT2 inhibitors, a class of medications originally developed for diabetes.

In the landmark EMPEROR-Preserved trial, empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by about 21% compared with placebo, driven mainly by fewer hospital admissions. The benefit held regardless of whether patients had diabetes.²⁴ A meta-analysis pooling data from the major SGLT2 inhibitor trials confirmed a 21% relative reduction in cardiovascular death or heart failure hospitalization across HFpEF patients, with consistent benefits in people without diabetes as well.²⁵ The effect on cardiovascular death alone trended in the right direction but has not yet reached statistical significance, so the main proven benefit so far is keeping people out of the hospital rather than extending life outright. Still, for a condition that lacked any effective drug therapy for years, SGLT2 inhibitors represent a genuine shift.

Sacubitril/valsartan, which combines a neprilysin inhibitor with an angiotensin receptor blocker, has shown mixed results in HFpEF. The large PARAGON-HF trial narrowly missed its primary endpoint. However, a smaller randomized trial in patients at the pre-heart-failure stage found that sacubitril/valsartan reduced major cardiovascular events compared with valsartan alone.²⁶ Whether this drug class works best in a specific slice of the HFpEF spectrum remains an open question.

Exercise and Cardiac Rehabilitation

Exercise is one of the few interventions that reliably improves how HFpEF patients feel, even when its effect on survival remains less clear. In the Ex-DHF-P trial, a supervised exercise program improved physical functioning, general health perception, vitality, social functioning, and overall quality of life. It also improved a heart-failure-specific quality of life score and reduced depressive symptoms.²⁷ These are not trivial gains. Many people with diastolic heart failure rate breathlessness and fatigue as their most distressing symptoms, and exercise training targets both.

Cardiac rehabilitation programs, which combine structured exercise with education and risk factor management, show similar prognostic effects in HFpEF and HFrEF patients.²⁸ That finding is encouraging because it means the benefits of rehab are not limited to the systolic form. Despite this, referral and enrollment rates for HFpEF patients remain low. Many patients are elderly, frail, or limited by joint problems, which makes structured exercise programs harder to access but arguably more important.

Why Standard Prediction Models Struggle With HFpEF

One persistent frustration for clinicians is that HFpEF does not behave like a single disease. It is increasingly viewed as a syndrome with multiple overlapping subtypes: an obesity-driven phenotype characterized by metabolic inflammation, a vascular-stiffness phenotype dominated by hypertension and aging, a right-heart-predominant phenotype linked to lung disease, and others. These subtypes carry different prognoses, respond differently to treatments, and muddy the waters when researchers try to find one-size-fits-all risk tools. The difficulty of predicting readmissions with standard scoring systems reflects this heterogeneity. A patient whose heart failure flares from uncontrolled blood pressure has a very different trajectory from someone whose primary driver is kidney failure or untreated sleep apnea.

This heterogeneity also explains why so many clinical trials in HFpEF historically came up empty. When a drug works for one subtype but not another, mixing everyone into a single trial can wash out a genuine effect. There is growing interest in phenotype-specific approaches, both for treatment and for prognosis, but the field has not yet settled on a standard way to classify patients into subtypes in routine practice. The best current advice for an individual patient seeking a personal prognosis is to look beyond the ejection fraction number. The severity of diastolic dysfunction, kidney function, diabetes status, frailty level, and NT-proBNP value together paint a far more accurate picture than any single measurement alone.

The Obesity Paradox

One counterintuitive wrinkle is the so-called “obesity paradox.” In some HFpEF studies, patients classified as obese had lower readmission rates than non-obese patients, and in the large readmission analysis, obesity was actually associated with lower odds of 30-day readmission.⁹ This pattern has shown up across several cardiovascular conditions and is still debated. Some researchers believe it reflects healthier metabolic reserves in overweight patients during acute illness, while others argue it is an artifact of earlier diagnosis: obese patients may get flagged and treated sooner because they are symptomatic at lower thresholds. Either way, the paradox does not mean that obesity is protective against HFpEF. As noted earlier, obesity drives disease onset and progression, makes diagnosis harder, and is a central feature of the most common HFpEF phenotype. The readmission finding is a statistical observation, not a reason to avoid weight management.

1
PubMed. Diastolic heart failure: predictors of mortality
2
PubMed. Mortality in diastolic heart failure: an update
3
PubMed Central. Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
4
PubMed Central. Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects
5
Cardiac Failure Review / Radcliffe Cardiology. Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
6
PubMed. Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target
7
PubMed. Mode of Death in Heart Failure With Preserved Ejection Fraction
8
Journal of Cardiac Failure. Sudden Cardiac Death in Patients with Diastolic Heart Failure
9
PubMed. Etiologies, Trends, and Predictors of 30-Day Readmissions in Patients With Diastolic Heart Failure
10
BMJ Open Quality. HOSPITAL Score, LACE Index and LACE+ Index as predictors of 30-day readmission in patients with heart failure
11
PubMed Central. Readmission Risk Trajectories for Patients With Heart Failure Using a Dynamic Prediction Approach: Retrospective Study
12
PubMed Central. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study
13
PubMed. Chronic kidney disease in patients with chronic heart failure–impact on intracardiac conduction, diastolic function and prognosis
14
PubMed Central. Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort
15
PubMed Central. Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
16
PubMed Central. Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review
17
Scientific Reports. Gender-related differences in heart failure with preserved ejection fraction
18
PubMed. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
19
PubMed. Prognostic Value of Frailty and Diastolic Dysfunction in Elderly Patients
20
Heart. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF
21
PubMed Central. Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction
22
Arquivos Brasileiros de Cardiologia. Prognostic Applications of Current Clinical Scores in Heart Failure with Preserved Ejection Fraction: A Prospective Cohort Study
23
Journal of the American Society of Echocardiography. Prognostic Value of Clinical Risk Scores and Exercise Echocardiography in Heart Failure with Preserved Ejection Fraction
24
PubMed. Empagliflozin in Heart Failure with a Preserved Ejection Fraction
25
PubMed Central. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis
26
JAMA Cardiology. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial
27
PubMed. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial
28
PubMed. Prognostic Effects of Cardiac Rehabilitation in Patients With Heart Failure (from a Multicenter Prospective Cohort Study)